Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide.

Aim: Advanced renal cancer has still a very poor prognosis. We combined wingless-related integration site (WNT) inhibitors with a bi-functional peptide, as previous research has proven their individual efficacy in cancer therapy. Each targets cancer cells differently.